3. Prognosis comparison among groups of TNBCs.
| Variablels | DFS [average
(range)] (month) |
Metastasis
[n/N (%)] |
5-year
DFS (%) |
OS [average
(range)] (month) |
Death
[n/N (%)] |
5-year
OS (%) |
| TNBC, triple negative breast cancer; cTNBC, conventional type of triple negative breast cancer; sTNBC, special type of triple negative breast cancer; LG, low grade; HG, high grade; DFS, disease-free survival; OS, overall survival. | ||||||
| All TNBCs | 38.32 (0−164) | 101/484 (20.9) | 73.8 | 40.79 (1−165) | 59/485 (12.2) | 82.3 |
| cTNBC | 38.51 (0−106) | 71/350 (20.3) | 75.0 | 40.72 (1−106) | 41/351 (11.7) | 83.9 |
| sTNBC | 37.81 (0−164) | 30/134 (22.4) | 70.5 | 40.97 (1−165) | 18/134 (13.4) | 76.9 |
| LG-TNBC | 40.09 (0−164) | 26/141 (18.4) | 75.5 | 42.70 (1−165) | 13/141 (9.2) | 84.9 |
| HG-TNBC | 37.59 (0−106) | 75/343 (21.9) | 72.9 | 40.01 (1−106) | 46/344 (13.4) | 81.0 |
| LG-cTNBC | 36.71 (0−97) | 12/65 (18.5) | 74.4 | 39.69 (1−97) | 4/65 (6.2) | 90.9 |
| HG-cTNBC | 38.92 (0−106) | 59/285 (20.7) | 75.0 | 40.95 (1−106) | 37/286 (12.9) | 82.3 |
| LG-sTNBC | 42.99 (1−164) | 14/76 (18.4) | 76.7 | 45.26 (1−165) | 9/76 (11.8) | 80.0 |
| HG-sTNBC | 31.03 (0−82) | 16/58 (27.6) | 62.2 | 35.34 (1−86) | 9/58 (15.5) | 72.4 |
| Apocrine carcinoma | 41.87 (1−164) | 12/67 (17.9) | 72.0 | 43.99 (1−165) | 9/67 (13.4) | 76.4 |
| Medullary carcinoma | 38.11 (5−73) | 2/19 (10.5) | 87.5 | 39.74 (5−73) | 0/19 (0) | 100.0 |
| Lobular carcinoma | 35.56 (0−93) | 5/16 (31.3) | 64.6 | 39.81 (3−93) | 3/16 (18.8) | 70.7 |
| Metaplastic carcinomas | 25.31 (0−64) | 9/26 (34.6) | 54.3 | 31.81 (1−86) | 6/26 (23.1) | 55.0 |